Sirolimus: a ten-year perspective (Q35687830)

9 August 2017

1 reference

title

Sirolimus: a ten-year perspective (English)

1 reference

9 August 2017

1 reference

Kahan BD

1

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

Transplantation Proceedings

9 August 2017

published in

1 reference

9 August 2017

volume

36

1 reference

9 August 2017

issue

1

1 reference

9 August 2017

page(s)

71-75

1 reference

Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.11.039

Rapamycin for immunosuppression in organ allografting.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.11.039

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.11.039

Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.11.039

The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.11.039

Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.11.039

Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.11.039

Determination of rapamycin in whole blood by HPLC

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.11.039

The quantification of sirolimus by high-performance liquid chromatography-tandem mass spectrometry and microparticle enzyme immunoassay in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.11.039

An immunoassay for the measurement of sirolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.11.039

Rapamycin: personal algorithms for use based on 250 treated renal allograft recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.11.039

Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.11.039

Toxicity and efficacy of sirolimus: relationship to whole-blood concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.11.039

Population pharmacokinetics of sirolimus in kidney transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.11.039

Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.11.039

Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.11.039

Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.11.039

The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.11.039

Efficacy and tolerability of interleukin-2 receptor blockade with basiliximab in pediatric renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.11.039

A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.11.039

Use of anti-CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.11.039

Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.11.039

Mycophenolate mofetil in pediatric renal transplantation without induction therapy: results after 12 months of treatment. German Pediatric Renal Transplantation Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.11.039

Sirolimus rescue therapy for refractory rejection in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.11.039

10.1016/J.TRANSPROCEED.2003.11.039

7 January 2021

Identifiers

DOI

1 reference

9 August 2017

1 reference